Daly Jason B. 4
4 · Amneal Pharmaceuticals, Inc. · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Daly Jason B.
EVP, Chief Legal Officer
Transactions
- Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-03+22,645→ 33,251 total - Tax Payment
Class A Common Stock
[F3]2026-03-03$13.31/sh−10,147$135,057→ 23,104 total - Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-03+38,226→ 61,330 total - Tax Payment
Class A Common Stock
[F3]2026-03-03$13.31/sh−16,598$220,919→ 44,732 total - Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-03+24,258→ 68,990 total - Tax Payment
Class A Common Stock
[F3]2026-03-03$13.31/sh−10,533$140,194→ 58,457 total - Exercise/Conversion
Class A Common Stock
[F4]2026-03-03+305,810→ 364,267 total - Tax Payment
Class A Common Stock
[F5]2026-03-03$13.31/sh−132,783$1,767,342→ 231,484 total - Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-04+35,880→ 267,364 total - Tax Payment
Class A Common Stock
[F3]2026-03-04$13.30/sh−15,580$207,214→ 251,784 total - Exercise/Conversion
Restricted Stock Units
[F2][F6]2026-03-03−22,645→ 0 total→ Class A Common Stock (22,645 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F7]2026-03-03−38,226→ 38,227 total→ Class A Common Stock (38,226 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F8]2026-03-03−24,258→ 72,774 total→ Class A Common Stock (24,258 underlying) - Exercise/Conversion
Performance-Based Restricted Stock Units
[F4]2026-03-03−305,810→ 0 total→ Class A Common Stock (305,810 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F9]2026-03-04−35,880→ 71,760 total→ Class A Common Stock (35,880 underlying)
Footnotes (9)
- [F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
- [F4]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
- [F5]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
- [F6]On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
- [F7]On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
- [F8]On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
- [F9]On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
Signature
/s/ Denis Butkovic, Attorney-in-Fact|2026-03-05